中文版 | English
Title

新的SERPINC1无义突变致抗凝血酶Ⅲ缺乏症并肺血栓栓塞症1例

Alternative Title
A novel SERPINC1 nonsense mutation causing an-tithrombin Ⅲ deficiency and pulmonary thromboem-bolism:a case report
Author
Publication Years
2023
DOI
Source Title
ISSN
1001-5213
Volume43Issue:3Pages:344-346
Abstract
抗凝血酶Ⅲ(antithrombin Ⅲ,AT Ⅲ)是人体凝血系统重要的抗凝血因子,可与肝素类药物结合形成药物-AT Ⅲ复合物,增强对活化凝血因子Ⅱ、Ⅸ、X、Ⅻ的抑制作用[1].AT Ⅲ缺乏是静脉血栓栓塞症(venous thromboembolism,VTE)的主要遗传性危险因素,可致肺血栓栓塞症(pulmona-ry thromboembolism,PTE).有文献报道遗传性AT Ⅲ缺乏症与SERPINC1基因突变密切相关[2-4].本文报道1例新的SERPINC1无义突变致严重的Ⅰ型遗传性ATⅢ缺乏症并肺血栓栓塞症病例,并结合相关指南及临床研究对其抗凝治疗进行探讨,为该类疾病诊治提供参考.
Keywords
URL[Source Record]
Language
Chinese
SUSTech Authorship
First
Funding Project
2021A23:广东省医院药学研究基金
Data Source
WanFang
WanFangID
zgyyyx202303020
Citation statistics
Cited Times [WOS]:0
Document TypeJournal Article
Identifierhttp://kc.sustech.edu.cn/handle/2SGJ60CL/524998
DepartmentSouthern University of Science and Technology
Affiliation
1.深圳市人民医院/暨南大学第二临床医学院/南方科技大学附属第一医院药学部,广东深圳 518020
2.深圳市人民医院/暨南大学第二临床医学院/南方科技大学附属第一医院呼吸与危重症医学科,广东深圳 518020
First Author AffilicationSouthern University of Science and Technology
First Author's First AffilicationSouthern University of Science and Technology
Recommended Citation
GB/T 7714
周桂保,古嘉瑜,陈秋玲,等. 新的SERPINC1无义突变致抗凝血酶Ⅲ缺乏症并肺血栓栓塞症1例[J]. 中国医院药学杂志,2023,43(3):344-346.
APA
周桂保,古嘉瑜,陈秋玲,李凯,刘盛国,&谢守霞.(2023).新的SERPINC1无义突变致抗凝血酶Ⅲ缺乏症并肺血栓栓塞症1例.中国医院药学杂志,43(3),344-346.
MLA
周桂保,et al."新的SERPINC1无义突变致抗凝血酶Ⅲ缺乏症并肺血栓栓塞症1例".中国医院药学杂志 43.3(2023):344-346.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Export to Excel
Export to Csv
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[周桂保]'s Articles
[古嘉瑜]'s Articles
[陈秋玲]'s Articles
Baidu Scholar
Similar articles in Baidu Scholar
[周桂保]'s Articles
[古嘉瑜]'s Articles
[陈秋玲]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[周桂保]'s Articles
[古嘉瑜]'s Articles
[陈秋玲]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.